Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorgenmeltucel-L - NewLink Genetics Corporation

Drug Profile

Dorgenmeltucel-L - NewLink Genetics Corporation

Alternative Names: HyperAcute Melanoma; Melanoma immunotherapy - NewLink Genetics; NLG-12036

Latest Information Update: 07 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines; Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma

Most Recent Events

  • 07 Aug 2015 Dorgenmeltucel-L is still in phase II trials for Malignant melanoma in the USA
  • 01 Apr 2014 NewLink Genetics Corporation initiates a phase IIb trial for Malignant melanoma in USA (NCT02054520)
  • 25 Feb 2014 NewLink Genetics Corporation plans a phase IIb trial for Malignant melanoma in USA (NCT02054520)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top